EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Association between body mass index and serum concentrations of olanzapine and selective serotonin reuptake inhibitors in patients with eating disorders

Vilde Hersleth, Olav Spigset, Siri Weider, Elise Koch, Ole A Andreassen, Stian Lydersen, Katrine Kveli Fjukstad

European Journal of Clinical Pharmacology · 2026

DOI: 10.1007/s00228-026-04175-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2026. Verfasst von Vilde Hersleth und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. Hauptthemen laut MEDLINE: Olanzapine, Selective Serotonin Reuptake Inhibitors, Body Mass Index, Antipsychotic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NTNU Norwegian University of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Selective serotonin reuptake inhibitors (SSRIs) and olanzapine are frequently prescribed for patients with anorexia nervosa and bulimia nervosa. The effect of severely low body mass index (BMI) on the pharmacokinetics of these drugs has received little attention. The aim was to investigate the association between BMI and dose-adjusted serum concentrations (concentration/dose ratios; CDRs) of SSRIs and olanzapine in patients with eating disorders.

Method

We conducted a retrospective analysis of patients from a regional center for eating disorders. BMI, daily doses of olanzapine and SSRIs, and their serum concentrations were obtained from medical records. Linear regression analyses were conducted with CDR for each drug as dependent variable and BMI as independent variable. A group of patients with schizophrenia or bipolar disorder was included for comparison of patients with BMI in the normal range.

Results

Sixty-five patients with eating disorders and 545 patients from the comparison group were included. Among the patients with eating disorders, there were no significant associations between BMI and CDRs for any of the drugs. CDR for olanzapine was significantly higher in the eating disorder group than in the comparison group, but most of this difference could be attributed to the higher proportion of smokers in the comparison group.

Conclusion

This study suggests that patients with eating disorders do not have clinically important changes in CDRs of SSRIs and olanzapine related to their low BMI. Although reassuring, the number of included patients treated with each drug is low.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OlanzapineSelective Serotonin Reuptake InhibitorsBody Mass IndexAntipsychotic AgentsFeeding and Eating DisordersBenzodiazepinesHumansFemaleRetrospective StudiesAdultMaleYoung AdultAdolescentSchizophrenia

Stichwörter der Autor:innen

Anorexia nervosaBody mass indexBulimia nervosaDrug concentrationsOlanzapineSelective serotonin reuptake inhibitorsTherapeutic drug monitoring

Substanzen

OlanzapineSelective Serotonin Reuptake InhibitorsAntipsychotic AgentsBenzodiazepines

Autor:innen und Institutionen

  • Department of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway.
  • Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Psychology, Faculty of Social and Educational Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
  • Eating Disorder Unit, Department of Psychiatry, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway.
  • Centre for Precision Psychiatry, Division of Mental Health and Addiction, Institute of Clinical Medicine, Oslo University Hospital, University of Oslo, Oslo, Norway.

Förderung

  • NTNU Norwegian University of Science and Technology

Zitieren

APA

Hersleth, V., Spigset, O., Weider, S., Koch, E., Andreassen, O. A., Lydersen, S., & Fjukstad, K. K. (2026). Association between body mass index and serum concentrations of olanzapine and selective serotonin reuptake inhibitors in patients with eating disorders. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-026-04175-8

Vancouver

Hersleth V, Spigset O, Weider S, Koch E, Andreassen OA, Lydersen S, et al. Association between body mass index and serum concentrations of olanzapine and selective serotonin reuptake inhibitors in patients with eating disorders. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-026-04175-8

BibTeX
@article{Hersleth2026,
  author = {Hersleth, Vilde and Spigset, Olav and Weider, Siri and Koch, Elise and Andreassen, Ole A and Lydersen, Stian and Fjukstad, Katrine Kveli},
  title = {Association between body mass index and serum concentrations of olanzapine and selective serotonin reuptake inhibitors in patients with eating disorders},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1007/s00228-026-04175-8}
}
Kostenlos starten →